Recent news from biopharmaceutical company
Regeneron Pharmaceuticals Inc. (REGN) covers a variety of topics. The company is currently under investigation by law firms like
Kirby McInerney LLP and Frank R. Cruz for potential shareholder claims and potential fraudulent price reporting for eye drug. In the recent earnings call, Regeneron reported
lower Eylea sales and missed forecasts, resulting in some underperformance compared to competitors. However, stock performance has also included several strong trading days and analysts from
Evercore ISI rated the company as a
Strong-Buy with Janney Montgomery Scott LLC, Massachusetts Financial Services Co., Almarack Investment Partners and others increasing their stakes. Still, CEO
Leonard S. Schleifer sold over
$35 million in company stocks. There's also mention of
gene editing collaboration with Doudna-founded Mammoth, but also a setback for a blood cancer therapy due to FDA concerns.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 02 Nov 2023 07:00:00 GMT to Thu, 16 May 2024 19:54:00 GMT -
Rating 0
- Innovation -2
- Information 7
- Rumor -3
